# XingImaging, LLC: Phase 1 study in Parkinsons Disease (PD), Healthy Elderly Volunteers (18 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | XingImaging, LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD) |
| NCT ID | NCT07880379 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Parkinsons Disease (PD); Healthy Elderly Volunteers |
| Intervention types | drug |
| Target enrollment | 18 |
| Site countries | United States |
| Posted | 2026-10-19 |
| Planned start | 2026-08-25 |
| Event | Newly registered study |
| Event date | 2026-10-19 |

## Why this score
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07880379). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.